med-tech recap preview
fda asbestos/talc meet
earn bmo preliminari sale bil organ
growth announc jan estim con topic org growth
driver catalyst color shortfal mgn trend watchman us lotu launch
earn bmo expect sale bil ep
rosa spine launch plan resolut qualiti suppli issu
expect week fda meet asbesto talc
expect meet result chang would materi impact jnj approach
talc busi afternoon session public speaker could skew
neg watch headlin reiter outperform rate price target
ew us tavr acceler nearli sale ep guid rais us tavr
grew nearli management reinvest upsid
market develop clinic field rep lead miss vs cse ep guid rais
tavr total sale expect around top end rang ew remain
top pick reiter outperform rais rais target
outstand knee implant growth sale
beat expect us knee implant growth wide margin gain
bp share vs cse market growth ww
placement vs estim guidanc line
highlight af symposium met number emerg privat compani
came away increment updat hot topic includ
puls field ablat use ai map diagnosi
ms index ytd bp bp ms
ltm vs ms led group week
lead ytd lc growth diversifi ms
ntm ev/ebitda respect vs
figur weekli perform suppli devic ms
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
figur upcom event catalyst
ticker potenti implic
read-through ortho spine
fda public meet test method asbesto talc
cosmet product contain talc
read-through cardio ew
advanc technolog treatment diabet attd
feb evolv role artifici intellig radiolog imag
read-through spine
intern societi advanc spine surgeri san
addit name confirm
holt weekli analysi ew rank attract
holt market impli expect rank ew rank
attract coverag univers holt analysi also suggest valuat remain
attract healthcar subsector put med-tech fairly-pr rang
figur week read research medic suppli devic
new decad disrupt begin highlight outlook suppli devic
solid end strong year guid call solid fundament rais sale project target price
digit disrupt acceler highlight docsf conf digit health ortho
highlight digit ortho meet
ew tavr acceler nearli ep guid rais reiter outperform top pick ew rais target price
highlight af symposium pfa ai rise innov
hospit survey take-away robot surgeri
organ growth ahead cse driven nutrit epd devic guid in-lin reiter outperform rais
fda meet asbesto talc agenda expect speaker present
med-tech recap preview
outperform-r report result februari market open compani
pre-announc preliminari sale bil januari estim
consensu topic call driver organ growth trend pipelin catalyst
driver op margin improv structur heart perform trend
updat lotu launch eu capit alloc note recent
investor sentiment survey rank second favorit name among investor
consist last quarter
med-tech recap preview
guidancecon cs estimate guidancecon cs estimate con cs in-lin better ep revenuesy/i growth growth growth growth growth growth growth growth growth growth neuromod epfocu endo infect prevent busi plan exalt-d launch spaceoar contribut focu sh includ watchman acur lotu uptak btg charl martineau pm univers toronto januari
underperform-r also report result februari model sale bil
cc organ ep topic call knee share trend
rosa tka commerci launch updat updat rosa spine commerci launch plan
updat resolut on-going qualiti suppli issu recent investor
sentiment survey jump place survey stock also
rank one name like miss expect survey
ww knee implant growth adjust estim mil robot sale report compani knee sale line consensu knee implant sale also calcul use credit suiss robot sale estim
med-tech recap preview
guidancecon cs estimate guidancecon cs estimate con cs growth growth growth growth growth growth implant growth robot growth growth growth growth growth growth growth growth growth growth rosa spine commerci launch new product launch special sale in-lin ep revenuesu knee implant continu grow market boost impact robot charl martineau pm univers toronto januari
receiv ce mark approv tendyn januari
announc ce mark approv tendyn transcathet mitral valv
implant tmvi system treat mitral regurgit patient requir
heart valv replac mr patient candid open-
heart surgeri transcathet mitral valv repair tendyn first mitral
replac valv market avail multipl size treat
broad rang valv anatomi tendyn also fulli reposition
retriev self-expand valv deliv small incis
chest heart implant beat heart
replac patient nativ mitral valv compani also expect run
post-approv studi trial current enrol
ec approv expand use erleada treat patient
mhspc januari announc european commiss
ec grant market author expand use erleada
apalutamid includ treatment adult men metastat
hormone-sensit prostat cancer mhspc combin androgen
depriv therapi approv base phase data
titan studi achiev statist signific dual primari
endpoint overal surviv os radiograph progression-fre surviv
rpf first pre-plan interim analysi studi erleada plu
androgen depriv therapi extend os compar placebo plu
reduct risk death also significantli improv
rpf compar placebo plu lower risk radiograph
progress death new indic erleada avail treat
peopl diagnos mcspc annual
context titan studi phase random placebo-control
double-blind studi includ patient diagnos mcspc
random erleada mg plu placebo plu
recal fda approv erleada septemb
treatment patient metastat castration-sensit prostat cancer
follow fda prioriti review design supplement new drug
applic snda submit april
launch respons coronaviru januari announc
initi effort develop vaccin candid
coronaviru vaccin program
advac technolog provid abil rapidli upscal
product optim vaccin candid context
technolog use develop manufactur jnj
investig ebola vaccin also use construct compani
zika rsv hiv vaccin candid multi-prong approach also
includ review known pathway coronaviru pathophysiolog
determin whether previous test medicin use help patient
surviv infect reduc sever diseas non-
lethal case compani partner biomed advanc
research develop author barda innov medicin
initi imi coalit epidem prepared innov
cepi coordin effort expect start phase clinic studi
order pay mil vaginal-mesh market
januari order pay mil misrepres risk
vaginal-mesh product california consum less
med-tech recap preview
mil state ask last year trial san diego superior court
judg eddi sturgeon conclud ethicon unit violat
california consumer-protect law multi-year market program
misl patient doctor danger product compani
establish accrual unknown amount respect product
liabil litig associ ethicon pelvic mesh product intend
appeal rule
med-tech recap preview
figur last week med-tech bp bp bp hc
med-tech recap preview
figur last month disrupt ms lead ms
med-tech recap preview
figur last month disrupt ms index outperform smid lc
disrupt ms index pro-rata weight perform alc ew base
proport revenu driven disrupt technolog
med-tech recap preview
figur ntm ev/ebitda coverag univers
med-tech recap preview
med-tech recap preview
holt market impli expect analysi indic valuat conserv
healthcar subsector holt use revers dcf quantifi market impli
expect calcul futur level return capit cfroi requir justifi
today valuat market impli expect green dot consensu
forecast pink bar indic attract valuat upsid potenti stock
figur healthcar holt cfroi ntm forecast return capit vs market-impli spread
note aggreg ex financi regul util reit data shown base constitu median
med-tech recap preview
return capit cfroi histor forecast market impli median industryspread forecast vs market impli return capitalconserv expect current price impli declin returnsdemand expect current price impli increas plife scitot hcmedtechcfroi year mediancfroi lfycfroi consensu forecast ntm market impli plife scitot hcmedtechposit spread currentneg spread year median charl martineau pm univers toronto januari
market impli expect coverag univers med-tech gener demand
rel sell side forecast holt market impli expect analysi reveal
attract consensu forecast cfroi market-impli
expect demand expect
figur med-tech holt cfroi ntm forecast return capit vs market-impli spread
contact inform holt
med-tech recap preview
spread currentneg spread year median mediancfroi lfycfroi consensu forecast ntm market impli cfroireturn capit cfroi histor forecast market impliedspread forecast vs market impli return capit conserv expect current price impli declin returnsdemand expect current price impli increas charl martineau pm univers toronto januari
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
price rate histori corp bsx
signifi initi assumpt coverag
price rate histori corp ew
signifi initi assumpt coverag
med-tech recap preview
price rate histori johnson johnson jnj
signifi initi assumpt coverag
price rate histori inc zbh
signifi initi assumpt coverag
decemb analyst stock rate defin follow
outperform stock total return expect outperform relev benchmark next month
neutral stock total return expect line relev benchmark next month
under-perform stock total return expect under-perform relev benchmark next month
relev benchmark region decemb japanes rate base stock total return rel analyst coverag univers
consist compani cover analyst within relev sector outperform repres att ractiv neutral less attract
underperform least attract invest opportun octob canadian well europea exclud turkey rate
base stock total return rel analyst coverag univers consist compani cover analyst within relev sector
outperform repres attract neutral less attract underperform least attract invest opportun latin america
turkey asia exclud japan australia stock rate base stock total return rel averag total return rele vant countri
region benchmark india bse sensex index prior octob canadian rate base stock absolut total return
potenti current share price rel attract stock total return potenti within anali ts coverag univers australian
new zealand stock expect total return calcul includ roll dividend yield outperform rate assign
greater equal under-perform less equal neutral may assign
overlap rate rang allow analyst assign rate put context associ risk prior may rang outperform
under-perform rate overlap neutral threshold oper juli
restrict certain circumst credit suiss polici and/or applic law regul preclud certain type commun
includ invest recommend cours credit suiss engag invest bank transact certain
circumst
rate nr credit suiss equiti research invest rate view stock secur relat
compani time
cover nc credit suiss equiti research provid on-going coverag compani offer invest rate
invest view equiti secur compani relat product
med-tech recap preview
volatil indic stock defin volatil stock price move month least
past month analyst expect signific volatil go forward
analyst sector weight distinct analyst stock rate base analyst expect fundament and/or
valuat sector rel group histor fundament and/or valuat
overweight analyst expect sector fundament and/or valuat favor next month
market weight analyst expect sector fundament and/or valuat neutral next month
underweight analyst expect sector fundament and/or valuat cautiou next month
analyst coverag sector consist compani cover analyst within relev sector analyst may cover mul tipl sector
credit suiss distribut stock rate bank client
bank client
purpos nyse finra rate distribut disclosur requir stock rate outperform neutral under-perform close
